PALO ALTO Calif., Oct. 12, 2012 /PRNewswire/ -- Inscopix, Inc. and SRI International today announced a collaborative neuroscience imaging R&D program. Researchers from Inscopix and SRI’s Center for Neuroscience and Metabolic Diseases will use Inscopix’s nVistaTMHDimaging system to gain a better understanding of normal brain function and the dysfunctions of neural circuitry that underlie neurological and neuropsychiatric disorders.
(Photo: http://photos.prnewswire.com/prnh/20121010/SF90026-b)
“Inscopix’s nVista HD technology will provide SRI researchers with an unparalleled view into brain activity that underlies both normal and diseased brain function,” said Thomas Kilduff, Ph.D., senior director of SRI’s Center for Neuroscience and Metabolic Diseases. “Since many brain diseases such as Alzheimer’s, autism, and schizophrenia are thought to involve dysfunction of neural circuitry, we expect to obtain novel insights that may lead to new therapeutic avenues for the treatment of neurological and neuropsychiatric disorders.”
SRI’s Center for Neuroscience and Metabolic Diseases has research programs in cognition and Alzheimer’s disease, Parkinson’s disease, sleep neurobiology and sleep disorders, nicotine addiction, alcoholism, and brain aging. Advanced imaging capabilities are needed to obtain a more complete understanding of the neural circuitry that underlies the functional activity of the brain. One research area of the collaborative effort will focus on identifying brain circuits that go awry in disease conditions or in the presence of a gene defect.
“Inscopix is extremely excited to be working with SRI’s Center for Neuroscience and Metabolic Diseases on this collaborative research project,” said Kunal Ghosh, Ph.D., Inscopix CEO. “Inscopix’s continued technology and application development will benefit tremendously via this project. At the same time Inscopix’s scientists are also looking forward to working with SRI’s researchers on pursuing new science uniquely enabled by nVista HD.”
SRI Biosciences and Inscopix are both exhibiting at Neuroscience 2012 (SfN) in New Orleans (booths #736 & #733, respectively).
About Inscopix, Inc.
Inscopix is a pioneering provider of in vivo cellular imaging solutions. Inscopix’s mission is to introduce a new dimension in neuroscience research to enable better clinical outcomes. With the nVista HD system, neuroscientists can now stream live, high definition videos of large-scale neural activity from the brain of an awake naturally behaving mouse. Data sets generated by nVista HD are unprecedented in scale and scope, and cannot be gathered by state-of-the-art imaging or electrophysiology recording techniques.
About SRI Biosciences
SRI Biosciences carries out basic research, drug discovery, and drug development, and provides contract (CRO) services. SRI has all of the resources necessary to take R&D from initial discovery to human clinical trialsand specializes in cancer, immunology and inflammation, infectious disease, and neuroscience. SRI’s product pipeline has yielded marketed drugs, therapeutics currently in clinical trials, and additional programs in earlier stages. In its CRO business, SRI has helped government and industry clients and partners advance many drugs into patient testing. SRI is also working to create the next generation of technologies in areas such as diagnostics, drug delivery, medical devices, and systems biology.
About SRI International
Innovations from SRI International have created new industries, billions of dollars of marketplace value, and lasting benefits to societytouching our lives every day. SRI, a nonprofit research and development institute based in Silicon Valley, brings its innovations to the marketplace through technology licensing, new products, and spin-off ventures. Government and business clients come to SRI for pioneering R&D and solutions in computing and communications, chemistry and materials, education, energy, health and pharmaceuticals, national defense, robotics, sensing, and more. For more information on SRI International, visit www.sri.com.
SOURCE Inscopix, Inc.
